Showing results (51-60 of 83) with videos related to
Sort By:
Pageof 9
Inflammatory Bowel Diseases|March 21, 2013
Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot studyHans H Herfarth, Jeffry A Katz, Stephen B Hanauer, et al.Inflammatory Bowel Diseases|September 7, 2016
Investigator-Initiated IBD Trials in the United States: Facts, Obstacles, and AnswersHans H Herfarth, Susan Jackson, Barbara G Schliebe, et al.Experimental Dermatology|June 4, 2021
Target molecules for future hidradenitis suppurativa treatmentChristos C Zouboulis, John W Frew, Evangelos J Giamarellos-Bourboulis, et al.Nature Communications|March 25, 2026
IgA autoantibodies promote inflammation, Th17 polarization and fibrotic responses in hidradenitis suppurativaCarmelo Carmona-Rivera, Liam J O'Neil, Eduardo Patino-Martinez, et al.American Journal of Clinical Dermatology|March 10, 2026
Defining Moderate Disease and Progression in Hidradenitis Suppurativa: An Expert Framework to Unlock the Window of Opportunity for Prompt TreatmentAntonio Martorell, John R Ingram, Christopher J Sayed, et al.The American Journal of Gastroenterology|October 15, 2009
NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn's disease in African AmericansThemistocles Dassopoulos, Geoffrey C Nguyen, Monica Vladut Talor, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|October 3, 2022
Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativaThrasivoulos Tzellos, Kelsey R van Straalen, Athanassios Kyrgidis, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|February 14, 2026
Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and IIThrasyvoulos Tzellos, Evangelos J Giamarellos-Bourboulis, Kelsey R van Straalen, et al.Inflammatory Bowel Diseases|July 13, 2015
MicroRNAs Classify Different Disease Behavior Phenotypes of Crohn's Disease and May Have Prognostic UtilityBailey C E Peck, Matthew Weiser, Saangyoung E Lee, et al.Journal of the American Academy of Dermatology|November 17, 2025
Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extensionChristopher J Sayed, Brian Kirby, Amit Garg, et al.Pageof 9